Jaguar Health Reports Q2 2026 Results: Full Earnings Call Transcriptbenzinga_article·Aug 19 at 04:18 PMJAGX+1.41%
JAGX: Q2 2026 revenue fell 60% year-over-year as focus shifted to rare disease drug developmentQuartr·Aug 19 at 03:16 PMJAGX+1.41%
Jaguar Health FY26 Q2 net loss narrows 80.7% to USD 4.08 million; revenue rises 314% to USD 21.5 millionPUBT·Aug 19 at 12:22 PMJAGX+1.41%
JAGX: License revenue boost drove a sharp reduction in net loss, but liquidity risks remainQuartr·Aug 19 at 12:19 PMJAGX+1.41%
Jaguar Health delays Q2 Form 10-Q filing after holdup compiling subsequent-event informationPUBT·Aug 14 at 04:28 PMJAGX+1.41%
Jaguar Health meets conditions to receive $2 million holdback payment from Future Pak license dealPUBT·Aug 5 at 08:00 AMJAGX+1.41%
12 Health Care Stocks Moving In Thursday's Intraday Sessionbenzinga_article·Jul 23 at 12:05 PMNUWE-8.65%ZYBT-3.08%
Jaguar Health announces press release on crofelemer compassionate use for infant MVID patient in EUPUBT·Jul 22 at 08:02 AMJAGX+1.41%
